The literature on pharmacogenomics as a tool to support antidepressant precision is
burgeoning. In this prospective, single-blind randomized controlled design, the impact of pharmacogenomics guided versus standard antidepressant was evaluated. Participants were 213 outpatients diagnosed with major depressive disorder and/
or generalized anxiety disorder, randomized to receive pharmacogenomics guided
(n = 105) or standard antidepressant treatment (n = 108); participants were blinded to
the study. Patient reported outcomes of depression, anxiety, disability, and treatment
satisfaction were assessed at months 0, 1, 3, and 6. Hypotheses were investigated
using mixed effect models on the full data. All clinical outcomes improved significantly.

A randomized controlled trial. Clin
Transl Sci. 2021;00:1–10.

Share this post